- Home
- PK vs CGON Comparison
PK vs CGON Comparison
Compare PK & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PK
- CGON
- Stock Information
- Founded
- PK 1946
- CGON 2010
- Country
- PK United States
- CGON United States
- Employees
- PK N/A
- CGON N/A
- Industry
- PK Real Estate Investment Trusts
- CGON
- Sector
- PK Real Estate
- CGON
- Exchange
- PK Nasdaq
- CGON NYSE
- Market Cap
- PK 2.1B
- CGON 2.0B
- IPO Year
- PK N/A
- CGON 2024
- Fundamental
- Price
- PK $11.38
- CGON $26.32
- Analyst Decision
- PK Hold
- CGON Strong Buy
- Analyst Count
- PK 11
- CGON 11
- Target Price
- PK $12.85
- CGON $63.30
- AVG Volume (30 Days)
- PK 3.5M
- CGON 955.4K
- Earning Date
- PK 07-31-2025
- CGON 08-07-2025
- Dividend Yield
- PK 12.31%
- CGON N/A
- EPS Growth
- PK 45.67
- CGON N/A
- EPS
- PK 0.61
- CGON N/A
- Revenue
- PK $2,602,000,000.00
- CGON $662,000.00
- Revenue This Year
- PK $2.45
- CGON N/A
- Revenue Next Year
- PK $2.92
- CGON $21,843.29
- P/E Ratio
- PK $18.66
- CGON N/A
- Revenue Growth
- PK N/A
- CGON 224.51
- 52 Week Low
- PK $8.27
- CGON $14.80
- 52 Week High
- PK $16.23
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- PK 63.14
- CGON 49.99
- Support Level
- PK $10.65
- CGON $24.50
- Resistance Level
- PK $11.31
- CGON $29.00
- Average True Range (ATR)
- PK 0.32
- CGON 1.48
- MACD
- PK 0.02
- CGON -0.04
- Stochastic Oscillator
- PK 81.11
- CGON 40.44
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels with 22,711 rooms across 37 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.